The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

US regulators grant full approval to Novavax shot but sharply limit eligibility. New studies on heart risks required, raising ...

The Food and Drug Administration has issued a long-awaited approval of Novavax's COVID-19 vaccine but with unusual restrictions. Novavax makes the nation's only traditional protein-based coronavirus ...

The vaccine will only be available to those at high risk from Covid—excluding those who may need it to protect a relative or ...

Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year ...

According to approval letter, the license restricts the use of vaccine called Nuvaxovid to individuals aged 65 and older, and ...

Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. Novavax ( NASDAQ:NVAX ) First Quarter 2025 ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the first quarter ended March 31, 2025. Novavax, Inc. (Nasdaq: NVAX) today announced that it will ...

Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. Novavax ( NASDAQ:NVAX ) First Quarter 2025 ...